Evaxion A (EVAX) Common Equity (2019 - 2026)
Evaxion A (EVAX) reported Common Equity of $13.2 million for Q1 2026, up 27.69% on a YoY basis from $10.3 million in Q1 2025, and down 22.49% quarter-over-quarter from $17.0 million in Q4 2025.
Evaxion A (EVAX) Common Equity (2019 - 2026) Analysis & Trends
Evaxion A has reported Common Equity for 8 years, with the latest figure at $13.2 million in Q1 2026.
- For the quarter ending Q1 2026, Common Equity rose 27.69% year-over-year to $13.2 million; the trailing twelve-month figure through Mar 2026 stood at $13.2 million (up 27.69% YoY), and the FY2025 full-year result was $17.0 million, up 1131.42% from the prior year.
- Common Equity for Q1 2026 stood at $13.2 million, down from $17.0 million in the prior quarter.
- The five-year high for Common Equity was $2.6 billion in Q1 2024, with the low at -$4.7 million in Q4 2023.
- Historically, Common Equity has averaged $171.6 million across 5 years, with a median of $9.3 million in 2022.
- Annual changes were most pronounced in 2023 — Common Equity sank 156.96% — and 2024, when it soared 31262.16%.
- Evaxion A's Common Equity stood at $8.3 million in 2022, then plunged by 156.96% to -$4.7 million in 2023, then soared by 65.07% to -$1.7 million in 2024, then surged by 1131.42% to $17.0 million in 2025, then fell by 22.49% to $13.2 million in 2026.
- The last three Common Equity figures came in at $13.2 million (Q1 2026), $17.0 million (Q4 2025), and $16.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 35.63 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.42 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 13.21 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 14.38 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 11.87 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.36 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 31.42 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.21 Mn |
| Dec 31, 2025 | 17.04 Mn |
| Sep 30, 2025 | 16.60 Mn |
| Jun 30, 2025 | 6.23 Mn |
| Mar 31, 2025 | 10.34 Mn |
| Dec 31, 2024 | -1.65 Mn |
| Jun 30, 2024 | 1.25 Mn |
| Mar 31, 2024 | 2.60 Bn |
| Dec 31, 2023 | -4.73 Mn |
| Sep 30, 2023 | -2.73 Mn |
| Jun 30, 2023 | 2.54 Mn |
| Mar 31, 2023 | 8.30 Mn |
| Dec 31, 2022 | 8.30 Mn |
| Sep 30, 2022 | 13.55 Mn |
| Jun 30, 2022 | 26.39 Mn |
| Mar 31, 2022 | 26.39 Mn |
| Dec 31, 2021 | 32.44 Mn |
| Sep 30, 2021 | 16.65 Mn |
| Jun 30, 2021 | 21.83 Mn |
| Mar 31, 2021 | 27.80 Mn |